Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Open Access
- 7 May 2012
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 122 (2), 444-455
- https://doi.org/10.1111/j.1471-4159.2012.07781.x
Abstract
J. Neurochem. (2012) 122, 444–455. Abstract Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma. Clinical benefit is more prominent in patients with methylation of the O6‐methyl‐guanine DNA methyltransferase (MGMT) promoter. However, all patients eventually suffer from tumor progression because their tumors become resistant to TMZ. Here, we modeled acquired TMZ resistance in glioma cells in vitro to identify underlying molecular mechanisms. To this end, the glioma cell lines LNT‐229, LN‐308, and LN‐18 were exposed repetitively to increasing concentrations of TMZ to induce a stable resistant phenotype (R) defined by clonogenic survival assays. The molecular mechanisms mediating acquired resistance were assessed by immunoblot, PCR, and flow cytometry. Rescue experiments were performed with siRNA‐mediated candidate gene silencing. We found in LN‐18 cells constitutively expressing MGMT a strong up‐regulation of MGMT levels in TMZ‐resistant cells. TMZ resistance in the MGMT‐negative cell lines LNT‐229 and LN‐308 was not associated with de novo expression of MGMT. Instead, we found a down‐regulation of several DNA mismatch‐repair proteins in resistant LNT‐229 cells. A TMZ‐resistant phenotype was also achieved by silencing selected DNA mismatch repair proteins in parental LNT‐229 cells. No obvious mechanism of resistance was identified in the third cell line, LN‐308, except for reduced methylation of LINE‐1 repetitive elements. In conclusion, we demonstrate that different molecular mechanisms may contribute to the development of acquired TMZ resistance in glioma cells, indicating the need to develop distinct strategies to overcome resistance.Keywords
This publication has 33 references indexed in Scilit:
- Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsJCI Insight, 2012
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomasInternational Journal of Cancer, 2011
- MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastomaInternational Journal of Cancer, 2010
- O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsNeuro-Oncology, 2010
- Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma PatientsClinical Cancer Research, 2009
- Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cellsCancer Cell International, 2006
- The Human LINE-1 Retrotransposon Creates DNA Double-strand BreaksJournal of Molecular Biology, 2006
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsThe New England Journal of Medicine, 2000
- Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormoneOncogene, 1999
- Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancerNature, 1994